ReviewRSC advances2025
Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- RNF125 mediates the anti-breast cancer activity of betulinic acid through ubiquitin-dependent degradation of MYH9.International journal of clinical oncology · 2026Article
- Novel Camptothecin-Based Lipid Conjugated with Steroids and Triterpene Acids: Enhanced Cellular Uptake and Topoismerase I Inhibition.Pharmaceutics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the leading cause of cancer-related death among women worldwide. Due to limited treatment options for patients with advanced BC, preventive and innovative therapeutic strategies are essential to combat this disease. Therefore, finding safe and effective anticancer treatments remains a significant challenge in the 21st century. Plant-derived triterpenoids, widely used for medicinal purposes, exhibit various biological activities. Most triterpenoids are cytotoxic to multiple tumor cells and demonstrate anticancer effects in preclinical animal models. One example is betulinic acid (BA), a natural product mainly extracted from the bark of birch trees. BA is a promising anti-tumor compound with numerous pharmacological properties. However, its poor water solubility limits its optimal therapeutic potential. Additionally, the low BA content in plants hampers large-scale production from these sources. To address these issues, extensive research has focused on producing BA through chemical synthesis and biotransformation. Furthermore, several BA derivatives have been developed through structural modifications, and various delivery systems have been created to improve solubility and enhance therapeutic efficacy. This review discusses recent advances and challenges related to BA and its derivatives in preventing and treating breast tumors, as well as the potential obstacles and future directions for improving delivery systems in BC therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.